APA (7th ed.) Citation

K, H., H, G., B, R., G, R., C, H., I, S., . . . Zahlten-Hinguranage, A. (2008). Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer, 8, 349. https://doi.org/10.1186/1471-2407-8-349

Chicago Style (17th ed.) Citation

K, Hoffmann, et al. "Prospective, Randomized, Double-blind, Multi-center, Phase III Clinical Study on Transarterial Chemoembolization (TACE) Combined with Sorafenib Versus TACE Plus Placebo in Patients with Hepatocellular Cancer Before Liver Transplantation - HeiLivCa [ISRCTN24081794]." BMC Cancer 8 (2008): 349. https://doi.org/10.1186/1471-2407-8-349.

MLA (9th ed.) Citation

K, Hoffmann, et al. "Prospective, Randomized, Double-blind, Multi-center, Phase III Clinical Study on Transarterial Chemoembolization (TACE) Combined with Sorafenib Versus TACE Plus Placebo in Patients with Hepatocellular Cancer Before Liver Transplantation - HeiLivCa [ISRCTN24081794]." BMC Cancer, vol. 8, 2008, p. 349, https://doi.org/10.1186/1471-2407-8-349.